Skip to main content
European Commission logo print header

Commercialisation of a world changing invention for the stabilisation and delivery of vaccines

Objective

Vaccination is an indispensable tool in fighting disease, annually saving up tens of millions of lives saved across the globe. Vaccines are biological products that are sensitive to temperature change and can lose their effectiveness if exposed to sub optimum temperatures. The delivery of vaccines from the factory to the customer currently relies on a closely monitored cold chain process containing a series of refrigerated storage units, designed to keep the vaccine at a constant temperature. The system frequently fails for a variety of reasons, some technical and some simply due to human error. Currently 50% of the world’s vaccines are rendered useless due to the failings of the present refrigerated ‘cold chain’ delivery systems
Stablepharma has a vision to eliminate the global cold chain and unnecessary vaccine wastage by introducing an innovative method to stabilise vaccines allowing them to be transported and stored at a wide-range of temperatures. Our technology involves the ~100% removal of liquid from vaccine dissolved in a special buffer, so that it is left in a completely stable and finely divided dry state absorbed into a, compressible, porous material that is in turn inserted into a standard auto-disable syringe. The process and invention was introduced to the WHO (World Health Organisation, Geneva) by invitation in 2012 and they have been able to assist the company with guidance in the development and accreditation process.
Stablepharma Ltd was incorporated in January 2012 to commercialise a revolutionary vaccine stabilisation invention and process developed and patented by our Chief Scientific Officer (CSO) and Chairman, Dr Bruce Roser, a pioneer and distinguished scientist in this field.

Call for proposal

H2020-SMEInst-2014-2015

See other projects for this call

Sub call

H2020-SMEINST-1-2015

æ

Coordinator

STABLEPHARMA LIMITED
Net EU contribution
€ 50 000,00
Address
1 queen square
BA1 2HA Bath
United Kingdom

See on map

SME

The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.

Yes
Region
South West (England) Gloucestershire, Wiltshire and Bristol/Bath area Bath and North East Somerset, North Somerset and South Gloucestershire
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Other funding
€ 21 429,00